Literature DB >> 16445295

Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation.

Zuzana Valnickova1, Trine Christensen, Peter Skottrup, Ida B Thøgersen, Peter Højrup, Jan J Enghild.   

Abstract

Thrombin-activable fibrinolysis inhibitor (TAFI) is distinct from pancreatic procarboxypeptidase B in several ways. The enzymatic activity of TAFIa is unstable and decays with a half-life of a few minutes. During this study, we observed that (i) the isoelectric point (pI) of TAFI shifts dramatically from pH 5 toward pH 8 upon activation and (ii) TAFIa is significantly less soluble than TAFI. The structural bases for these observations were investigated by characterizing all post-translational modifications, including attached glycans and disulfide connectivity. The analyses revealed that all five potential N-glycosylation sites were utilized including Asn22, Asn51, Asn63, Asn86 (located in the activation peptide), and Asn219 (located in the catalytic domain). Asn219 was also found in an unglycosylated variant. Four of the glycans, Asn51, Asn63, Asn86, and Asn219 displayed microheterogeneity, while the glycan attached to Asn22 appeared to be homogeneous. In addition, bisecting GlcNAc attached to the trimannose core was detected, suggesting an origin other than the liver. Monosaccharide composition and LC-MS/MS analyses did not produce evidence for O glycosylation. TAFI contains eight cysteine residues, of which two, Cys69 and Cys383, are not involved in disulfides and contain free sulfhydryl groups. The remaining six cystines form disulfides, including Cys156-Cys169, Cys228-Cys252, and Cys243-Cys257. This pattern is homologous to pancreatic procarboxypeptidase B, and it is therefore unlikely that permutations in the cysteine connectivity are responsible for the enzymatic instability. LC-MS/MS analyses covering more than 90% of the TAFI amino acid sequence revealed no additional modifications. When these results are taken together, they suggest that the inherent instability of TAFIa is not caused by post-translational modifications. However, after activation, TAFIa loses 80% of the attached glycans, generating a large shift in pI and a propensity to precipitate. These changes are likely to significantly affect the properties of TAFIa as compared to TAFI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16445295     DOI: 10.1021/bi051956v

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates.

Authors:  Zuzana Valnickova; Laura Sanglas; Joan L Arolas; Steen V Petersen; Christine Schar; Daniel Otzen; Francesc X Aviles; F Xavier Gomis-Rüth; Jan J Enghild
Journal:  J Biol Chem       Date:  2010-09-29       Impact factor: 5.157

2.  The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa.

Authors:  Kanchan Anand; Irantzu Pallares; Zuzana Valnickova; Trine Christensen; Josep Vendrell; K Ulrich Wendt; Herman A Schreuder; Jan J Enghild; Francesc X Avilés
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

3.  Carbohydrates and activity of natural and recombinant tissue factor.

Authors:  Jolanta Krudysz-Amblo; Mark E Jennings; Kenneth G Mann; Saulius Butenas
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

4.  α(1,3)-Fucosyltransferases FUT4 and FUT7 control murine susceptibility to thrombosis.

Authors:  Huili Wang; Maria Morales-Levy; Jason Rose; Lantz C Mackey; Peter Bodary; Daniel Eitzman; Jonathon W Homeister
Journal:  Am J Pathol       Date:  2013-04-02       Impact factor: 4.307

5.  Virtual 2-D map of the fungal proteome.

Authors:  Tapan Kumar Mohanta; Awdhesh Kumar Mishra; Adil Khan; Abeer Hashem; Elsayed Fathi Abd-Allah; Ahmed Al-Harrasi
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

Review 6.  Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

Review 7.  Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.

Authors:  Nikoletta Pechlivani; Katherine J Kearney; Ramzi A Ajjan
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

8.  Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).

Authors:  Zuzana Valnickova; Morten Thaysen-Andersen; Peter Højrup; Trine Christensen; Kristian W Sanggaard; Torsten Kristensen; Jan J Enghild
Journal:  BMC Biochem       Date:  2009-05-05       Impact factor: 4.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.